Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937352 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 3 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 896
- Enrollment target
NCT00937352: Clinical Trial Phase 3 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT00937352 is a Phase 3 study that was terminated before completion, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 896 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00937352, a Phase 3 study, was terminated before completion, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 896 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
Interventions
- DRUG Bapineuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 896 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00937352
The ClinicalTrials.gov registry entry for NCT00937352 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 896 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bapineuzumab is the first listed.
NCT00937352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00937352 about?
NCT00937352 is a clinical study titled "A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease". The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
What is the current status of trial NCT00937352?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 896 participants. The study started on 2009-07. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00937352?
The interventions under investigation include: Bapineuzumab (DRUG).
Who is sponsoring clinical trial NCT00937352?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.